Glp-1

If GLP-1 drugs only treated diabetes and did not promote weight loss, they would still be medically groundbreaking.

An apparent conflict between WeightWatchers, which promotes a non-medical, points-based approach to food intake, and the talkshow host came in December when she told People magazine that she integrated GLP-1 drugs, brands that include Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, into her existing “holistic approach” of “regular exercise and other lifestyle tweaks”.

Some brides say explicitly that they are using GLP-1s, while for others, Ms. Yang, who said she uses Mounjaro herself, has her suspicions.

Its lawyers said it could no longer service a $1.6bn debt load because of an “evolution in consumer preferences and the rapid rise of GLP-1s”, and it was seeking an aggregate valuation of $700mn.

Those days are gone. WeightWatchers and its commercial diet program peers have struggled to maintain market share in the era of GLP-1s, the class of drugs that includes Ozempic, Wegovy and Mounjaro, which give users a much higher chance of success.

Consumers are also increasingly embracing wellness trends while others are on GLP-1s or medications that curb their desire to snack on sweet or salty foods.